Seeking Alpha
 

Intra-Cellular Therapies Inc. (ITCI)

- NASDAQ
  • Mon, May 18, 8:47 AM
    • At the American Psychiatric Association meeting in Toronto, Intra-Cellular Therapies (NASDAQ:ITCI) presented additional data from a 335-subject Phase 2 clinical trial evaluating its lead product candidate, ITI-007, in patients with schizophrenia.
    • The study met its primary efficacy endpoint of a statistically significant improvement in psychosis as measured by the change from baseline at day 28 in PANSS total score versus placebo.
    • Patients in the intent-to-treat population who received once-daily 60 mg ITI-007 showed improved negative symptoms as did a subgroup of those with prominent negative symptoms. The effects were not observed in patients treated with risperidone (branded version: Janssen Pharmaceuticals' (NYSE:JNJ) Risperdol). Also, a subgroup of schizophrenia patients who had co-morbid depression that were treated with ITI-007 showed a statistically significant anti-psychotic effect not observed in the risperidone cohort.
    • Treatment with ITI-007 demonstrated a favorable tolerability profile with little or no weight gain, favorable effect on metabolic measures and a reduced risk of akathisia (feeling of restlessness) and hyperprolactinemia (elevated prolactin in the blood which may cause breast enlargement in men).
    • ITI-007 is currently in Phase 3 development.
    • ITCI is up 5% premarket on light volume.
    | Comment!
  • Thu, May 7, 12:09 PM
    • Tonix Pharmaceuticals (TNXP +0.7%) initiated with Buy rating and $10 (63% upside) price target by Janney Capital.
    • Infinity Pharmaceuticals (INFI -0.5%) initiated with Buy rating and $20 (67% upside) price target by Deutsche Bank.
    • Intra-Cellular Therapies (ITCI -0.8%) initiated with a Buy rating and $50 (138% upside) price target by SunTrust Robinson Humphrey.
    • Onconova Therapeutics (ONTX +1.7%) initiated with Buy rating and $6 (153% upside) price target by H.C. Wainwright.
    • CONMED (CNMD +0.9%) initiated with Buy rating and $63 (18% upside) price target by Deutsche Bank.
    • Carbylan Therapeutics (CBYL +1.8%) initiated with Outperform rating and $16 (183% upside) price target by Leerink Swann.
    • NovaBay Pharmaceuticals (NBY -6.5%) initiated with Buy rating and $2 (251% upside) price target by Maxim Group.
    • Rosetta Genomics (ROSG -0.6%) initiated with Outperform rating and $8 (229% upside) price target by Barrington Research.
    • Lion Biotechnologies (LBIO -0.5%) initiated with Buy rating and $30 (162% upside) price target by Chardan Capital.
    • Shire plc (SHPG +0.5%) initiated with Outperform rating by Exane BNP Paribas.
    | Comment!
  • Thu, Apr. 30, 7:28 AM
    • Intra-Cellular Therapies (NASDAQ:ITCI): Q1 EPS of -$0.72 misses by $0.11.
    • Revenue of $0.03M (-82.4% Y/Y) misses by $0.02M.
    • Press Release
    | Comment!
  • Thu, Mar. 12, 7:29 AM
    • Intra-Cellular Therapies (NASDAQ:ITCI): Q4 EPS of -$0.52 misses by $0.15.
    • Revenue of $0.07M (-91.6% Y/Y) misses by $0.05M.
    • Press Release
    | Comment!
  • Wed, Mar. 11, 4:33 PM
    • Intra-Cellular Therapies (NASDAQ:ITCI) closes its public offering of 4.75M shares of common stock at $24 per share. Underwriters exercised an option to purchase an additional 661,481 shares which was ~93% of the total over-allotment of 712,500. Net proceeds were ~$121.4M.
    | Comment!
  • Thu, Mar. 5, 9:48 PM
    • Intra-Cellular Therapies (NASDAQ:ITCI) prices its public offering of 4.75M shares of common stock at $24 per share. Underwriters over-allotment is an additional 712.5K shares. Closing date is March 11. Net proceeds will be ~$106.5M.
    | Comment!
  • Wed, Feb. 18, 12:51 PM
    | Comment!
  • Nov. 3, 2014, 8:57 AM
    • Intra-Cellular Therapies (ITCI +2.6%) Q3 results: Revenues: $0.1M (-85.7%); R&D Expense: $4M (-4.8%); G&A: $2.6M (100.0%); Operating Loss: ($6.5M) (-35.4%); Net Loss: ($6.4M) (-28.0%); Loss Per Share: ($0.22) (+21.4%); Quick Assets: $136M (+265.6%).
    • No guidance given.
    | Comment!
  • Nov. 3, 2014, 7:20 AM
    • Intra-Cellular Therapies (NASDAQ:ITCI): Q3 EPS of -$0.22 beats by $0.06.
    • Revenue of $0.12M (-81.8% Y/Y).
    • Press Release
    | Comment!
  • Oct. 27, 2014, 12:43 PM
    • Intra-Cellular Therapies (ITCI +0.5%) will report Q3 results on November 3 before the open. The conference call will begin at 8:30 am ET.
    • Consensus view is a loss of ($0.28) per share on revenues of $110K.
    | Comment!
  • Aug. 12, 2014, 9:25 AM
    • Intra-Cellular Therapies (NASDAQ:ITCI) Q2 results: Revenues: $0.2M (-65.9%); Net Loss: ($4.5M) (+45.2%); Loss Per Share: ($0.15) (+73.2%); Quick Assets: $140.5M (+277.7%).
    • No financial guidance given.
    | Comment!
  • Aug. 12, 2014, 7:37 AM
    • Intra-Cellular Therapies (NASDAQ:ITCI): Q2 EPS of -$0.15 beats by $0.08.
    • Revenue of $0.22M (-65.6% Y/Y) misses by $0.19M.
    • Press Release
    | Comment!
  • Mar. 25, 2014, 4:51 PM
    | Comment!
Visit Seeking Alpha's
ITCI vs. ETF Alternatives
Company Description
Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is engaged in discovery and clinical development ofsmall molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders.